Asset acquisitions - Ayala Pharmaceuticals - Fair value of assets and liabilities (Details) - USD ($) $ in Thousands	Mar. 25, 2024	Mar. 31, 2024	Dec. 31, 2023
Assets acquired:
Total assets		$ 319,754	$ 148,540
Liabilities assumed:
Total liabilities		$ 34,182	$ 28,658
Ayala Purchase Agreement
Asset acquisitions
Common stock issued to Ayala	$ 50,645
Upfront consideration paid to Ayala	20,039
Transaction costs	657
Consideration paid	71,341
Assets acquired:
In-process research and development	73,382
Total assets	73,382
Liabilities assumed:
Accrued expenses	2,041
Total liabilities	2,041
Net assets acquired	$ 71,341